This week, we’re highlighting stories about itch. Read about more topics here.
 
Covid-19 Update
 
Telemedicine can help practices thrive during the COVID-19 crisis
Jules Lipoff, M.D., dermatologist and assistant professor of clinical dermatology, Penn Medicine, discusses telemedicine in the era of COVID-19.
 
Acne and Rosacea
 
An update on antibiotic use for acne
Read insights from James Q. Del Rosso, D.O., as he discusses antibiotic resistance, isotretinoin relapse, and laboratory monitoring for patients on isotretinoin and spironolactone.
 
Novel topical foam promising for papulopustular rosacea
Published results from two 12-week, vehicle-controlled phase 3 studies show that a novel topical foam formulation of minocycline 1.5% may be effective in reducing inflammatory lesions.
 
Psoriasis and Atopic Dermatitis
 
Psoriasis: An update on topical therapies
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.
 
 
Phase 3 results show abrocitinib safe, effective for atopic dermatitis
Pfizer announces top-line results from its third phase 3 clinical trial investigating abrocitinib in adults with moderate-to-severe atopic dermatitis.
 
Skin Cancer
 
A paradigm shift in squamous cell carcinoma treatment
Recent advances in systemic therapies have led to the development of PD-1 checkpoint inhibitors, which one expert says may represent a paradigm shift in the treatment and management of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC).

Connect with us on Twitter and Facebook for daily updates.
 
 
From our Latest Issue
 
Dermatology Times cover
Interleukin-29 for inflammatory autoimmune diseases
 
Standard of care for primary cutaneous melanoma evolves
 
Adjunct therapies may support fractional CO2